- 100% NATURAL PRODUCT: No artificial colors or flavors
- Verified herb identity, confirmed highest quality of raw herb and the extract
- Best natural sources of herbs and raw materials: Every vendor is carefully picked to meet our high standards
- Third-party lab tested, pure Artemisinin
Artemisinin, has been for over two millennia, one of the most common herbs prescribed in traditional Chinese medicine (TCM)(1).
Artemisinin acts in a multi-specific manner also against hematological malignancies. The chemical structure of Artemisinin is a sesquiterpene lactone, which contains an endoperoxide bridge essential for activity. The main mechanism of action of Artemisinin and its derivatives(artesunate, dihydroartemisinin, artemether) toward leukemia, multiple myeloma, and lymphoma cells comprises oxidative stress response, inhibition of proliferation, induction of various types of cell death as apoptosis, autophagy, ferroptosis, inhibition of angiogenesis, and signal transducers, as NF-κB, MYC, amongst others.
Many in vivo experiments in disease-relevant animal models demonstrate therapeutic efficacy of artemisinin-type drugs against rheumatic diseases (rheumatoid arthritis, osteoarthritis, lupus erythematosus, arthrosis, and gout), lung diseases (asthma, acute lung injury, and pulmonary fibrosis), neurological diseases (autoimmune encephalitis, Alzheimer's disease, and myasthenia gravis), skin diseases (dermatitis, rosacea, and psoriasis), inflammatory bowel disease, and other inflammatory and autoimmune diseases.
Keywords: Artemisia annua L.; Artemisinin; Artesunate;
| Items |
Specifications |
Results |
Test Methods |
| Physical and Chemical |
| Loss on Drying |
≤ 10.0% |
Conforms |
GB 5009.3 |
| Residue on Ignition |
≤ 6.0% |
Conforms |
GB 5009.4 |
| Mesh Size |
95% pass 80 mesh |
Conforms |
CP2020 |
| Appearance |
Green to brown powder |
Conforms |
Visual |
| Odor & Taste |
Characteristic |
Conforms |
Organoleptic |
| Contaminants |
| Arsenic (As) |
≤ 0.50 mg/kg |
0.276 mg/kg |
ICP-MS||GB 5009.268 |
| Lead (Pb) |
≤ 2.00 mg/kg |
1.070 mg/kg |
ICP-MS||GB 5009.268 |
| Mercury (Hg) |
≤ 0.05 mg/kg |
0.011 mg/kg |
ICP-MS||GB 5009.268 |
| Cadmium(Cd) |
≤ 0.50 mg/kg |
0.153 mg/kg |
ICP-MS||GB 5009.268 |
| Microbiological |
| Total Plate Count |
≤ 1,000 cfu/g |
Conforms |
GB 4789.2 |
| Mold&Yeast |
≤ 100 cfu/g |
<10 cfu/g |
GB 4789.15 |
| E. Coli |
<10 cfu/g |
Conforms |
GB 4789.38 |
| Salmonella |
Absent/25g |
Conforms |
GB4789.4 |
| Staphylococcus aureus |
<10 cfu/g |
Conforms |
GB4789.10 |
| Package |
Inside package: Double food grade plastic bags(N.W.: 5KG, 25KG). Outside package: Cartons/fiber drums. |
| Storage |
Stored in a well-closed container away from light, heat and moisture |
| Shelf Life |
3 years if sealed and stored under the recommended conditions |
* The statements in this section have not been evaluated by the FDA or EFSA.
References
1. Mancuso RI, Foglio MA, Olalla Saad ST. Artemisinin-type drugs for the treatment of hematological malignancies. Cancer Chemother Pharmacol. 2021;87(1):1-22. doi:10.1007/s00280-020-04170-5
2. Kiani BH, Kayani WK, Khayam AU, Dilshad E, Ismail H, Mirza B. Artemisinin and its derivatives: a promising cancer therapy. Mol Biol Rep. 2020;47(8):6321-6336. doi:10.1007/s11033-020-05669-z
3. Efferth T, Oesch F. The immunosuppressive activity of artemisinin-type drugs towards inflammatory and autoimmune diseases. Med Res Rev. 2021;41(6):3023-3061. doi:10.1002/med.21842
4. Tong X, Chen L, He SJ, Zuo JP. Artemisinin derivative SM934 in the treatment of autoimmune and inflammatory diseases: therapeutic effects and molecular mechanisms. Acta Pharmacol Sin. 2022;43(12):3055-3061. doi:10.1038/s41401-022-00978-4
Audited Supplier 
){kind=link}
){kind=link}